Last updated: September 30, 2026
Glycopyrrolate has a fragmented product market spanning tablets, oral solutions, injections, dry-powder inhalers, nebulized suspensions and fixed-dose inhaled combinations. The strongest excipient opportunities are in pediatric oral liquids, inhalation products, preservative-free parenterals and differentiated combination products. Excipient selection can improve tolerability, dose uniformity, device performance and regulatory substitutability, but it rarely creates durable exclusivity by itself.
What pharmaceutical formulations contain glycopyrrolate?
Glycopyrrolate, also called glycopyrronium bromide in some markets, is a quaternary ammonium antimuscarinic. Its permanent positive charge limits passive central nervous system penetration and supports local respiratory delivery. The drug is used for secretion control, perioperative anticholinergic treatment and maintenance bronchodilation in chronic obstructive pulmonary disease.
| Product or product type |
Route |
Typical commercial role |
Excipient strategy |
| Glycopyrrolate tablets |
Oral |
Anticholinergic treatment |
Conventional tablet fillers, binders and lubricants |
| Cuvposa |
Oral solution |
Pediatric chronic drooling and secretion control |
Palatability, pH control, aqueous stability |
| Glycopyrrolate injection |
Intravenous or intramuscular |
Perioperative use |
Sterility, isotonicity, preservative control |
| Seebri Neohaler |
Dry-powder inhalation |
COPD maintenance |
Lactose carrier and inhaler capsule performance |
| Lonhala Magnair |
Nebulized inhalation |
COPD maintenance |
Aqueous inhalation solution and nebulizer compatibility |
| Bevespi Aerosphere |
Metered-dose inhaler |
Glycopyrrolate/formoterol COPD treatment |
Suspension stability, propellant and device compatibility |
| Utibron Neohaler |
Dry-powder inhalation |
Indacaterol/glycopyrrolate COPD treatment |
Carrier-based powder engineering |
| Breztri Aerosphere |
Metered-dose inhaler |
Budesonide/glycopyrrolate/formoterol COPD treatment |
Triple-drug suspension and aerosol performance |
The product-specific excipient profile is controlled by the approved labeling and chemistry, manufacturing and controls documentation. FDA labeling identifies lactose, magnesium stearate, citric acid, sodium citrate, sweeteners, flavoring agents and water-based vehicles in relevant products, although the precise composition differs by dosage form and manufacturer (U.S. Food and Drug Administration [FDA], 2010, 2015, 2016, 2017, 2020).
Which glycopyrrolate dosage forms offer the largest commercial opportunity?
The highest-value opportunities are differentiated oral liquids and inhaled products rather than standard tablets.
Pediatric oral liquids
Cuvposa was approved in the United States in 2010 for chronic severe drooling associated with neurologic conditions in children. The product is administered according to weight, making dose measurement and palatability commercially important.
A competitive oral-liquid platform can target:
- Sugar-free and alcohol-free formulations
- Reduced sodium content
- Improved flavor masking
- Lower viscosity for oral syringes
- Better chemical stability after opening
- Unit-dose packaging for institutional use
- Pediatric dosing in smaller volume increments
- Preservative-free packaging where microbiological control permits
Glycopyrrolate is bitter, and its anticholinergic effects can complicate adherence. Taste masking should focus on bitterness suppression rather than simply increasing sweetness. Ion-pairing, polymeric taste blockers, flavor systems and pH optimization may support differentiation, but each approach requires assessment of assay, dissolution, dose uniformity and stability.
A pediatric product also needs a dosing device strategy. An oral syringe calibrated for weight-based dosing can reduce administration error and create a combination-product or device-related differentiation point. The formulation should maintain uniform concentration throughout the labeled shelf life and after repeated opening.
Inhaled dry powders
Dry-powder glycopyrrolate products generally use carrier-based powder systems. Lactose is a common inhalation carrier because it supports powder handling and dose metering. The commercial challenge is not merely selecting lactose. It is controlling particle-size distribution, surface morphology, moisture, fine-particle fraction and capsule emptying.
Potential development strategies include:
- Engineered lactose with controlled fines
- Spray-dried or spray-freeze-dried glycopyrrolate particles
- Carrier-free particles
- Amino-acid or phospholipid surface modification
- Moisture-resistant packaging
- Lower-resistance inhaler platforms
- Improved dose consistency across inspiratory-flow rates
For a generic dry-powder inhaler, the excipient system cannot be evaluated separately from the inhaler. FDA approval requires a product that is pharmaceutically equivalent and therapeutically equivalent under the applicable pathway. Device resistance, emitted dose, aerodynamic particle-size distribution and patient-use performance can become significant development barriers.
Nebulized solutions
Lonhala Magnair uses glycopyrrolate delivered through a nebulizer system. Nebulized solutions offer an opportunity for patients who cannot reliably generate the inspiratory flow required by some dry-powder devices.
Commercially relevant formulation targets include:
- Preservative-free sterile solution
- Low osmolality burden
- Controlled pH
- Minimal residual volume
- Reduced foaming
- Short administration time
- Compatibility with reusable or disposable nebulizers
- Low extractables and leachables risk
For nebulized glycopyrrolate, excipient simplicity is generally valuable. Surfactants, preservatives and complex co-solvent systems may increase pulmonary tolerability, toxicology and device-compatibility burdens. A sterile, isotonic or near-isotonic aqueous formulation with robust container closure performance is generally easier to position than a chemically complex alternative.
What excipients are relevant to glycopyrrolate oral formulations?
Oral tablets
Conventional tablet opportunities are primarily cost and supply-chain driven. Useful excipient changes may include:
- Direct-compression filler systems
- Low-moisture formulations
- Improved hardness without delayed disintegration
- Reduced tablet size
- Film coating for taste and handling
- Lactose-free or low-lactose alternatives
- Robust packaging for high-humidity markets
The active ingredient is administered at relatively low strength, so blend uniformity is central. Low-dose content uniformity can favor ordered mixing, engineered excipients or granulation approaches. A formulation change that improves manufacturability without changing release behavior may support a differentiated generic or a 505(b)(2) product, depending on the proposed labeling and clinical claims.
Oral solutions
The main excipient variables are pH, buffering capacity, sweetener system, flavor, viscosity and preservative approach.
| Formulation objective |
Candidate strategy |
Primary technical risk |
| Bitterness reduction |
Flavor modulation, polymeric taste masking |
Reduced dose accuracy or precipitation |
| Chemical stability |
Citrate or alternative buffer system |
pH-dependent degradation |
| Pediatric acceptability |
Noncariogenic sweeteners and fruit flavors |
Flavor instability or allergen concerns |
| Dose measurement |
Low-viscosity aqueous vehicle |
Spillage and inaccurate administration |
| Preservative-free presentation |
Unit-dose or validated multidose closure |
Microbial contamination |
| Global market access |
Sugar-free and alcohol-free vehicle |
Lower solubility or palatability |
The most defensible commercial position is usually a complete product platform: formulation, dosing device, packaging and patient-use data. An excipient-only claim is less likely to block competitors than a formulation combined with a specific concentration, pH range, container or administration system.
What excipients are used in inhaled glycopyrrolate products?
Dry-powder inhalers
Lactose-based carrier systems are common, but they create several design constraints. Glycopyrrolate must remain adequately dispersed from the carrier during inhalation. Excessive carrier adhesion can lower fine-particle delivery. Excessive detachment can create dose variability and device-retention problems.
Key control variables are:
- Active particle size and morphology.
- Carrier particle-size distribution.
- Fine lactose content.
- Relative humidity exposure.
- Powder electrostatics.
- Capsule puncture and emptying.
- Inhaler airflow resistance.
- Emitted dose and aerodynamic particle-size distribution.
A proprietary carrier treatment or inhaler geometry may provide stronger protection than a basic lactose substitution. The same excipient platform may also support lifecycle expansion into glycopyrrolate combinations with formoterol, indacaterol or inhaled corticosteroids.
Metered-dose inhalers
Bevespi Aerosphere and Breztri Aerosphere use pressurized metered-dose inhaler technology. In these products, the formulation depends on a suspended drug system, propellant behavior, valve metering and actuator performance.
Commercial opportunities include:
- Improved suspension homogeneity
- Reduced settling or creaming
- Lower valve retention
- More consistent emitted dose
- Lower throat deposition
- Reduced actuator deposition
- Improved stability during temperature cycling
- Alternative propellant strategies
The transition from older hydrofluoroalkane propellants to lower-global-warming-potential propellants creates a major platform opportunity. Any reformulation must preserve dose delivery, particle size, device function and clinical performance. A propellant change can require substantial comparative characterization and, depending on the product and regulatory strategy, clinical bridging.
What patent protection can cover glycopyrrolate formulations?
Glycopyrrolate itself is an established active ingredient, so commercial protection is more likely to arise from product architecture than from basic composition-of-matter rights.
Formulation patents
Potential claim categories include:
- Specific glycopyrrolate concentrations
- Defined pH or buffer ranges
- Stabilized aqueous solutions
- Preservative-free formulations
- Taste-masked oral liquids
- Specific lactose carrier distributions
- Spray-dried or engineered particles
- Propellant-based suspensions
- Container closure systems
- Nebulizer-compatible formulations
- Moisture-protective packaging
Formulation patents are strongest when the claimed composition is linked to measurable performance, such as improved stability, reduced variability or superior pulmonary deposition. Broad claims covering routine excipient substitution are more vulnerable to written-description, enablement and obviousness challenges.
Method-of-use patents
Glycopyrrolate method-of-use protection may cover:
- Chronic drooling in defined pediatric populations
- COPD maintenance treatment
- Specific dosing schedules
- Use through a particular delivery device
- Combination treatment with a long-acting beta agonist or inhaled corticosteroid
- Reduction of exacerbations or improvement in lung function
Method-of-use patents can remain commercially relevant after composition patents expire, but enforcement depends on label language, induced-infringement evidence and the actual conduct of generic manufacturers.
Device and combination-product patents
For inhaled products, the commercially relevant patent estate may include:
- Inhaler airflow paths
- Capsule handling
- Metering valves
- Actuators
- Nebulizer components
- Dose counters
- Drug-device interfaces
- Formulation-device combinations
These rights can be more difficult to design around than a single excipient patent because the product must meet both pharmaceutical and device performance requirements.
What is the FDA Orange Book status of glycopyrrolate products?
The Orange Book identifies approved drug products, therapeutic-equivalence evaluations and, where applicable, listed patents and exclusivity information. Glycopyrrolate products must be assessed individually by NDA, dosage form, route and reference product. A single conclusion for "glycopyrrolate" is not accurate because oral, injectable and inhaled products have separate regulatory records (FDA, 2024a).
| Regulatory issue |
Commercial implication |
| Listed drug status |
Determines the reference product for an ANDA |
| Orange Book patents |
Can trigger Paragraph IV certification and litigation |
| Method-of-use listings |
May allow a skinny-label generic strategy |
| Inhaler reference product |
Requires complex product and device comparison |
| Exclusivity |
Can delay ANDA approval even when patents are absent |
| 505(b)(2) pathway |
May support reformulated or new-delivery glycopyrrolate products |
An ANDA applicant challenging an Orange Book-listed patent may submit a Paragraph IV certification. The NDA holder can file suit within 45 days, triggering a statutory stay of FDA approval of up to 30 months, subject to statutory exceptions and case-specific outcomes under the Hatch-Waxman framework.
When does glycopyrrolate lose exclusivity?
Glycopyrrolate exclusivity is product-specific. The original active ingredient is old, but individual formulations and combination inhalers may have later patent and regulatory dates.
The relevant analysis should separate:
- Active-ingredient age
- NDA approval date
- New chemical entity exclusivity, if applicable
- Pediatric exclusivity
- Orphan-drug exclusivity, where applicable
- Orange Book patent expiration
- Patent-term adjustment or extension
- Regulatory exclusivity for new dosage forms
- Device and formulation patents
- Litigation-related approval stays
Key U.S. glycopyrrolate milestones include:
| Product |
Sponsor or commercial holder |
FDA milestone |
| Cuvposa oral solution |
Shionogi-related product history |
Approved in 2010 |
| Seebri Neohaler |
Novartis |
Approved in 2015 |
| Utibron Neohaler |
Novartis |
Approved in 2015 |
| Bevespi Aerosphere |
AstraZeneca |
Approved in 2016 |
| Lonhala Magnair |
Theravance Biopharma and partners |
Approved in 2017 |
| Breztri Aerosphere |
AstraZeneca |
Approved in 2020 |
These dates do not determine patent expiration. Patent expiration requires review of the relevant U.S. patent, terminal disclaimers, patent-term adjustment and any patent-term extension. FDA’s Orange Book and the USPTO Patent Center are the controlling sources for current status.
Which companies compete in glycopyrrolate products?
The competitive landscape includes branded respiratory companies, generic manufacturers and contract development organizations.
Branded competition
- AstraZeneca: Bevespi Aerosphere and Breztri Aerosphere
- Novartis: Seebri Neohaler and Utibron Neohaler
- Theravance Biopharma and commercial partners: Lonhala Magnair
- Shionogi-associated product history: Cuvposa
Generic and platform competition
Generic companies can compete in:
- Tablets
- Oral solutions
- Injection
- Dry-powder inhalers
- Inhaled fixed-dose combinations
The highest barrier is generally the inhaled combination market. Generic applicants must address product sameness, device performance, aerodynamic delivery and, in some cases, complex clinical or comparative requirements. Standard oral and injectable glycopyrrolate products generally present lower technical barriers, although low-dose uniformity and sterile manufacturing remain important.
What licensing opportunities exist for glycopyrrolate?
Licensing opportunities are most credible in delivery technology and combination products.
Potential transaction structures include:
- In-licensing a pediatric oral-liquid platform
- Acquiring a preservative-free nebulized formulation
- Licensing a low-global-warming-potential inhaler platform
- Co-developing glycopyrrolate with a long-acting beta agonist
- Licensing a carrier-engineered dry-powder system
- Out-licensing regional rights for generic or branded products
- Contract-manufacturing agreements for sterile solution or inhalation products
A licensee should evaluate ownership of formulation patents, freedom to operate on device components, manufacturing know-how, regulatory data rights, stability data and rights to improvements. The most valuable know-how may be unpublished process information rather than an excipient claim.
How strong is the glycopyrrolate patent estate?
The estate is strongest around branded inhaled combinations, proprietary inhalers and formulation-device systems. It is weaker around conventional oral tablets and basic glycopyrrolate solutions because the active ingredient and common excipients are established.
| Product segment |
Patent strength |
Main barrier |
| Conventional tablets |
Low to moderate |
Limited formulation differentiation |
| Oral solution |
Moderate |
Taste, stability and dosing-device claims |
| Injection |
Low to moderate |
Sterile manufacturing and supply reliability |
| Dry-powder inhaler |
Moderate to strong |
Device, carrier and aerodynamic performance |
| Nebulized solution |
Moderate |
Device compatibility and sterile formulation |
| Dual-combination inhaler |
Stronger |
Combination, device and formulation claims |
| Triple-combination inhaler |
Stronger |
Multiple active ingredients and device system |
What generic launch scenarios exist?
A generic launch strategy can follow several paths:
- Early paragraph IV challenge: Appropriate where Orange Book patents are vulnerable and market size justifies litigation.
- At-risk launch: Offers earlier revenue but exposes the applicant to damages and injunction risk.
- Skinny-label launch: Removes patented method-of-use indications while retaining nonprotected uses.
- Post-expiration launch: Lower litigation risk but may face multiple competitors.
- 505(b)(2) reformulation: Targets improved taste, delivery, dosing or tolerability rather than direct substitution.
- Device-specific generic launch: Potentially attractive in inhalation, but technically demanding.
Revenue exposure is highest for fixed-dose inhalers with multiple indications and established COPD market access. A generic that launches only after core combination patents expire may still encounter device patents, supply constraints and payer substitution barriers.
What are the geographic opportunities for glycopyrrolate?
The U.S. market has the clearest Orange Book and Paragraph IV framework. Europe and other major markets require separate review of national validation, supplementary protection certificates, centralized or decentralized marketing authorizations, device requirements and local substitution rules.
Regional opportunities include:
- Pediatric oral liquids in markets with limited ready-to-use products
- Preservative-free injections in hospital channels
- Generic inhalation products in countries with reference-product substitution
- Low-cost nebulized products where dry-powder inhalers have lower penetration
- Reformulated inhalers using lower-emission propellants
- Contract manufacturing for emerging markets
A global excipient strategy should avoid unnecessary reliance on excipients with complex regional status, variable compendial specifications or limited inhalation precedent.
Key Takeaways
- Glycopyrrolate has commercial opportunity across oral, injectable, nebulized and inhaled products.
- Pediatric oral liquids offer the clearest excipient-led differentiation through taste, stability and dosing accuracy.
- Inhaled products offer higher revenue potential but require integrated formulation-device development.
- Lactose carrier engineering, moisture control and aerodynamic performance are central to dry-powder products.
- Preservative-free sterile solutions are attractive for both oral and inhaled delivery where packaging can support microbiological control.
- Patent strength is concentrated in inhaler devices, fixed-dose combinations, formulations and method-of-use claims.
- Conventional tablets and injections are more exposed to generic competition.
- Orange Book status, patent-term calculations and Paragraph IV risk must be reviewed by individual product and dosage form.
- Licensing value is highest in delivery platforms, combination inhalers and pediatric administration systems.
- Excipient substitution alone rarely creates durable market exclusivity without associated performance, device or manufacturing claims.
FAQs
Can glycopyrrolate be formulated as a sugar-free pediatric liquid?
Yes. A sugar-free aqueous formulation can use noncariogenic sweeteners, flavor systems and pH control. The main development risks are bitterness, chemical stability, dose uniformity and microbial control.
Is lactose essential in glycopyrrolate dry-powder inhalers?
No. Lactose is a common carrier, but alternative carriers and carrier-free engineered particles are possible. Any substitute must meet inhalation performance, safety, stability and device requirements.
Can a new glycopyrrolate formulation qualify for a 505(b)(2) application?
Potentially. A new delivery route, formulation, dosage form or dosing system may support a 505(b)(2) strategy if the proposed application relies partly on FDA findings for an approved glycopyrrolate product and satisfies applicable bridging requirements.
What is the main barrier to a generic glycopyrrolate inhaler?
The main barrier is integrated product performance. The applicant must address formulation sameness, emitted dose, aerodynamic particle-size distribution, device operation, stability and, where applicable, comparative clinical requirements.
Do excipient patents protect glycopyrrolate products after active-ingredient patents expire?
They can, but only if the claims are valid, enforceable and commercially relevant to the marketed product. The strongest claims usually connect excipient composition with a defined performance result, device configuration or manufacturing process.
References
- U.S. Food and Drug Administration. (2010). Cuvposa (glycopyrrolate) oral solution prescribing information.
- U.S. Food and Drug Administration. (2015). Seebri Neohaler (glycopyrrolate inhalation powder) prescribing information.
- U.S. Food and Drug Administration. (2015). Utibron Neohaler (indacaterol/glycopyrrolate) prescribing information.
- U.S. Food and Drug Administration. (2016). Bevespi Aerosphere (formoterol fumarate/glycopyrrolate) prescribing information.
- U.S. Food and Drug Administration. (2017). Lonhala Magnair (glycopyrrolate) prescribing information.
- U.S. Food and Drug Administration. (2020). Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) prescribing information.
- U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024b). Draft guidance for industry: Metered dose inhaler and dry powder inhaler drug products.
- United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary.
